Zobrazeno 1 - 10
of 116
pro vyhledávání: '"NICHOLS, T. C."'
Autor:
NICHOLS, T. C.1 tnichols@med.unc.edu, RAYMER, R. A.1, FRANCK, H. W. G.1, MERRICKS, E. P.1, BELLINGER, D. A.1, DeFRIESS, N.1, MARGARITIS, P.2, ARRUDA, V. R.2, KAY, M. A.3, HIGH, K. A.2,4
Publikováno v:
Haemophilia. May2010 Supplement 3, Vol. 16, p19-23. 5p.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
MERRICKS, E. P., DICKNEITE, G., NICHOLS, T. C., NOLTE, M. W., ZOLLNER, S., PRAGST, I., MUELLER-COHRS, J.
Prophylaxis of hemophilia B, at present, requires multiple infusions of human factor IX (FIX) concentrates per week. A FIX molecule with a prolonged half-life has the potential to greatly improve convenience of, and adherence to, prophylaxis.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c1be0f46dd493752815688c98425b083
Autor:
Agersø, H., Stennicke, H. R., Ezban, M., deFriess, N. A., Olsen, E. N., Merricks, E. P., Pelzer, H., Nichols, T. C.
The objective of the present study was to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of the new recombinant FVIII compound turoctocog alfa and a Glyco-PEGylated FVIII derivative thereof (N8-GP) in Haemophilia A dogs. Six haem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::15010ca0374f63494f86302a09c45249
Autor:
KNUDSEN, T., KRISTENSEN, A. T., NICHOLS, T. C., AGERSØ, H., JENSEN, A. L., KJALKE, M., EZBAN, M., TRANHOLM, M.
Recombinant human FVIIa (rhFVIIa) corrects the coagulopathy in hemophilia A and B as well as FVII deficiency. This is also the case in dogs until canine anti-human FVIIa antibodies develop (~2 weeks). Recombinant canine factor VIIa (rcFVIIa), success
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1d40ffa60832a34c9b1f04a448a4f59c
https://europepmc.org/articles/PMC3925423/
https://europepmc.org/articles/PMC3925423/
Autor:
KARPF, D. M., AGERSØ, H., NICHOLS, T. C., DEFRIESS, N., KJALKE, M., EZBAN, M., THIM, L., MERRICKS, E. P.
N8, a new recombinant factor VIII (rFVIII) compound developed for the treatment of haemophilia A, is produced in Chinese hamster ovary (CHO) cells and formulated without human- or animal-derived materials. The aim of the present study was to compare
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::83c6f110267eb8b68dac26253d8dfe8c
Autor:
Bellinger, D. A., Arruda, V. R., Nichols, T. C., High, K. A., Franck, H. W. G., Merricks, E. P., Raymer, R. A., Dillow, A. M.
Dogs with hemophilia A, hemophilia B, von Willebrand disease (VWD), and factor VII deficiency faithfully recapitulate the severe bleeding phenotype that occurs in humans with these disorders. The first rational approach to diagnosing these bleeding d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dc23fac4cc913fc29b7dd2ccab3c4370
Autor:
RAGNI, M. V., NICHOLS, T. C., CHAPMAN, H. L., JANKOWITZ, R. C., DILLOW, A. M., MERRICKS, E. P., KLOOS, M. T.
von Willebrand factor (VWF) is a multimeric glycoprotein that mediates platelet adhesion and is decreased in von Willebrand disease (VWD). 1-8 deamino-d-arginine vasopressin (DDAVP), the most common treatment for VWD, is limited by tachyphylaxis and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f06a32fc10e0bad6b3bf7546fdbf3a66
Autor:
McCORMACK, W. M., BERTIN, T. K., PALMER, D. J., NG, P., SEILER, M. P., UBHAYAKAR, K., NICHOLS, T. C., LEE, B.
Adenoviral vector-mediated gene therapy might have potential for long-term correction of the monogenic disease hemophilia A.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::20adeae49ba9b5046b4c4b07d1d68fc0